ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development

Reuters

06-27

ProQR <a href="https://laohu8.com/S/LENZ">Therapeutics</a> NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development

ProQR Therapeutics NV has announced the submission of a Clinical Trial Application $(CTA.UK)$ to the European Medicines Agency $(EMA)$ for their lead pipeline program, AX-0810, marking a significant advancement for their Axiomer™ RNA editing platform. This first-in-human Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and target engagement of AX-0810 in healthy volunteers. AX-0810 targets NTCP, a liver cell protein, to potentially reduce toxic bile acid accumulation and address cholestatic liver diseases. The trial is set to begin at a single site in the Netherlands, with initial data expected in Q4 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114982-en) on June 26, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546592877"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546592877\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2546592877?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546592877","market":"fut","top_or_hot":-1,"title":"ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ProQR Therapeutics NV has announced the submission of a Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> to the European Medicines Agency <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> for their lead pipeline program, AX-0810, marking a significant advancement for their Axiomer™ RNA editing platform. This first-in-human Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and target engagement of AX-0810 in healthy volunteers. AX-0810 targets NTCP, a liver cell protein, to potentially reduce toxic bile acid accumulation and address cholestatic liver diseases. The trial is set to begin at a single site in the Netherlands, with initial data expected in Q4 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114982-en) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-27 04:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ProQR Therapeutics NV has announced the submission of a Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> to the European Medicines Agency <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> for their lead pipeline program, AX-0810, marking a significant advancement for their Axiomer™ RNA editing platform. This first-in-human Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and target engagement of AX-0810 in healthy volunteers. AX-0810 targets NTCP, a liver cell protein, to potentially reduce toxic bile acid accumulation and address cholestatic liver diseases. The trial is set to begin at a single site in the Netherlands, with initial data expected in Q4 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114982-en) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDLJn2SX:1","article_id":"2546592877","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546592877","pubTimestamp":1750969822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer RNA Editing Platform Development. ProQR Therapeutics NV has announced the submission of a Clinical Trial Application  to the European Medicines Agency  for their lead pipeline program, AX-0810, marking a significant advancement for their Axiomer RNA editing platform. This first-in-human Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and target engagement of AX-0810 in healthy volunteers. AX-0810 targets NTCP, a liver cell protein, to potentially reduce toxic bile acid accumulation and address cholestatic liver diseases. The trial is set to begin at a single site in the Netherlands, with initial data expected in Q4 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PRQR":"ProQR Therapeutics N.V.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"ProQR Therapeutics NV提交AX-0810靶向NTCP的首次人体研究临床试验申请，标志着Axiomer的里程碑™RNA编辑平台开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PRQR":0.9},"content_text":"ProQR Therapeutics NV Submits Clinical Trial Application for First Human Study of AX-0810 Targeting NTCP, Marking Milestone in Axiomer™ RNA Editing Platform Development\n    \n\n        ProQR Therapeutics NV has announced the submission of a Clinical Trial Application $(CTA.UK)$ to the European Medicines Agency $(EMA)$ for their lead pipeline program, AX-0810, marking a significant advancement for their Axiomer™ RNA editing platform. This first-in-human Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and target engagement of AX-0810 in healthy volunteers. AX-0810 targets NTCP, a liver cell protein, to potentially reduce toxic bile acid accumulation and address cholestatic liver diseases. The trial is set to begin at a single site in the Netherlands, with initial data expected in Q4 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001114982-en) on June 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}